[Asia Economy Reporter Hyunseok Yoo] NKMax announced on the 16th that its U.S. subsidiary NKGen Biotech has newly appointed a Chief Medical Officer (CMO).
Dr. Steven Cha, who joined as the new CMO, earned a bachelor's degree in Cell Biology from the University of California and obtained his doctorate from Tufts University School of Medicine. He has over 15 years of experience in research and development at companies such as Amgen, Allergan, Pfizer, Puma Biotechnology, and Biosplice (formerly Sumumed LLC), leading the development of anticancer cell therapies including CAR-T.
Sangwoo Park, CEO of NKMax, stated, “Dr. Steven Cha, who joined as CMO, is an expert in the field of cell therapy. Together with CFO Philip Moody and CTO Steven Chen, they form a dream team that will focus their capabilities on the growth of the U.S. subsidiary through the upcoming allogenic NK and CAR-NK clinical trials.” He expressed great expectations for future business progress.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
